CELL AND GENE THERAPY INSIGHTS

September 2026 Issue

Volume 12 Issue 8

Cell and Gene Therapy Insights Volume 12 Issue 8
Download PDF

Featuring

Issue Spotlight: Manufacturing scale-up/scale-out and automation
Other articles
Webinars

SPOTLIGHT

Manufacturing scale-up/scale-out and automation

Expert Insight

Education and training for the cell and gene therapy sector: initiatives, gaps and future opportunities

Education and training for the cell and gene therapy sector: initiatives, gaps and future opportunities

Gary Gilleskie, Elissa Hudspeth
7 September
Read
ATMP development and market access in Europe and the United States: why scientific innovation alone no longer wins

ATMP development and market access in Europe and the United States: why scientific innovation alone no longer wins

Jens Kurth , Günter Harms
7 September
Read

Review

Hidden translation costs in cell and gene therapy manufacturing

Hidden translation costs in cell and gene therapy manufacturing

Robert E Nordon
10 September
Read

Innovator Insight

Evaluation of ice recrystallization inhibitors for preserving the post-thaw function of iPSC-derived natural killer cells

Evaluation of ice recrystallization inhibitors for preserving the post-thaw function of iPSC-derived natural killer cells

Anna Jezierski, Robert N Ben
21 September
Read
Scale-up and process transfer considerations in lentiviral vector manufacturing

Scale-up and process transfer considerations in lentiviral vector manufacturing

Jonathan Zmuda, Shin Kawamata
28 April
Read

Infographic

End-to-end CAR-T manufacturing workflow

End-to-end CAR-T manufacturing workflow

21 September
Read
Cell processing in cell therapy manufacturing

Cell processing in cell therapy manufacturing

10 September
Read
Accelerating AAV biosafety testing to 1–2 weeks with validated NGS workflows

Accelerating AAV biosafety testing to 1–2 weeks with validated NGS workflows

Andrew Hillhouse
3 September
Read

Interview

Building an autologous CAR-T manufacturing network from scratch: infrastructure, workforce, and what comes next

Building an autologous CAR-T manufacturing network from scratch: infrastructure, workforce, and what comes next

Frederik Buysse
15 September
Read
From feasibility to access: how is cell therapy’s central challenge evolving?

From feasibility to access: how is cell therapy’s central challenge evolving?

Christian Chabannon
5 August
Read

Tech Showcase

Unlocking high-yield, cost-efficient EV manufacturing through fixed-bed bioreactors

Unlocking high-yield, cost-efficient EV manufacturing through fixed-bed bioreactors

Thomas Robert
6 October
Read
Rapid, simple purification of AAV using low-speed centrifugation

Rapid, simple purification of AAV using low-speed centrifugation

Michael Dzuricky
30 September
Read

articles

Innovator Insight

Characterizing extracellular vesicles across analytical and process development

Characterizing extracellular vesicles across analytical and process development

Davide Zocco
7 September
Read

Infographic

Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

8 October
Read

Interview

Potency, off-target analysis, and comparability in in vivo gene-edited therapy development

Potency, off-target analysis, and comparability in in vivo gene-edited therapy development

Kok-Seong Lim
7 October
Read
Scaling up and scaling out: expanding patient access with in vivo CAR-T

Scaling up and scaling out: expanding patient access with in vivo CAR-T

Grant Boldt
7 October
Read

Event Preview

Event preview of the World Orphan Drug Congress 2026

Event preview of the World Orphan Drug Congress 2026

2 October
Read

Tech Showcase

Achieve over 98% viability and up to a 10% recovery increase in automated leukapheresis cryopreservation

Achieve over 98% viability and up to a 10% recovery increase in automated leukapheresis cryopreservation

Alice Bouchoms
16 September
Read

Webinars